Novo Nordisk faces investor calls for strategy beyond Wegovy

Investors and analysts are urging Novo Nordisk CEO Mike Doustdar to outline the company's strategy beyond its blockbuster weight-loss drug Wegovy, calling for medium-term targets and acquisitions to counter looming patent cliffs and competition from Eli Lilly.